Monday, November 16, 2026 Never miss a recall or a rule change Get the free brief →
Inside MedSpa
FDA Recall & Compliance Alerts for Medspa Owners
Business & M&AInMode Q3 revenue holds near $92.1M, margins slip3 days agoRegulatoryJudge bars Medicare price for Botox over plasma rulelast weekRegulatoryMexico approves Restylane Shaype for jawline first3 days agoBusiness & M&AEvolus posts Q3 loss of $0.09, revenue tops estimateslast weekBusiness & M&ACoty shareholders approve 50M-share equity plan boost4 days agoMarketAllergan posts nine ASDS abstracts, two on GLP-1 patientslast weekDevices & TechConexeu's first human collagen batch meets its own specs5 days agoBusiness & M&AGalderma lifts 2026 sales outlook to 22.5-23.5%last weekBusiness & M&AMedytox Q3 operating profit up 74.5% on toxin sales5 days agoBusiness & M&ACytrellis Brings ellacor into UM Nurse Practitioner Courselast weekRegulatoryTrifluent recalls Tridacaine III lidocaine patch6 days agoRegulatoryFDA clears Shenzhen Bway red/NIR LED face mask6 days ago
Regulatory

Mexico approves Restylane Shaype for jawline first

Galderma's firmer HA gel now has a Mexican approval for jawline definition, the first anywhere in the world for that area.

Scientist in a lab coat handling test tubes under pink lighting, using a microscope.
Photo: Artem Podrez / Pexels

Get the free Inside MedSpa brief by email

The free Inside MedSpa brief · no card · unsubscribe anytime. Privacy.

Primary document: Mexico Becomes the First Market Worldwide to Receive Approval for Galderma’s Restylane ® Shaype™ for Both Chin and Its First Jawline Indicat · Published: 2026-11-13

Galderma announced on November 13, 2026 that Mexican regulators have approved Restylane Shaype for temporary chin enhancement and for sharpening jawline definition. The company's release, carried by sttinfo.fi, calls it the product's first approval for the jawline anywhere. The filing's regulator is Mexico's, not the FDA's. The release does not name the agency or the approval date.

Free alerts

Free: recall & rule-change alerts for your practice.

Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.

The free Inside MedSpa brief · no card · unsubscribe anytime. Privacy.

Mexico is the first market worldwide to approve Restylane Shaype for the jawline.

The chin was already the product's established indication. Galderma says Restylane Shaype is approved for chin augmentation in Europe, Brazil, Canada and Thailand. Mexico adds a second indication in the same market, which matters more for a Mexican clinic than the headline does.

What changed

Galderma says the product is a firmer gel built to deliver a bone-mimicking effect. The release says the gel runs on the company's new NASHA HD technology and has the highest G' (its firmness measure) of the Restylane range. That is the number to bring to a supplier call. The release also says the gel is among the firmest HA fillers on the market from the leading brands, though it names no competitors.

The company also introduced a new, next-generation syringe. It says the syringe lets users work more precisely thanks to an ergonomic design and a revised syringe-needle connection. Galderma pairs the product with a training method it calls the Shayping Technique. That method uses the company's AART framework and the Facial Assessment Scale to guide how practitioners evaluate patients.

The clinical numbers, as Galderma reports them

The release cites a key 12-month chin study. In it, 83 percent of people showed improved structure and definition at three months, and 66 percent at 12 months. Galderma says 84 percent would agree to be treated again.

For the jawline, the company cites a study in which the product outperformed no treatment in restoring definition, with gains lasting up to two years. Seventy percent reported better overall satisfaction. A separate jawline study reports over 92 percent would recommend it to a friend.

These are sponsor-reported figures. The release gives no study size, no control design for the chin trial, and no dropout numbers. The 97 percent recommend-to-a-friend figure comes from a satisfaction survey, not an efficacy measure. Treat it as marketing until you see the protocol.

What it means for practices

Analysis: the jawline is the commercial reason for this release. Chin filler is crowded. A jawline claim with a defined scope gives a clinic a service to name on a menu and a reason to revisit patients who already had lower-face work. Galderma says the chin is the third most treated area among existing HA users, based on its own market research. That research is not described in the release, so ask for it before you build a campaign around it.

The release ties the product to medication-driven weight loss and menopause. Those are real demand drivers in Mexico and elsewhere, but the release offers no data specific to either group. It is positioning, not evidence.

What owners can do

Ask your distributor for the Mexican registration documents, the approved jawline wording and the labeled use. The release says "approved indications vary by market," so do not assume the Mexican label carries over to the chin label in your country.

Check whether the Shayping Technique training is available in your market and who delivers it. Galderma describes it as a way to standardize assessment, so clinics that skip it will have no record of why they treated what they treated.

Ask about the new syringe. Test it on a non-patient session before it goes into a booked case. The release describes a changed connection, and you will want to know how it handles against your current stock.

If you are outside Mexico, the approval does not reach you. Chin use under your local label is the only thing you can book now.

What we don't know yet

The release does not give the Mexican approval date, the registration number, the dosing or injection volumes, or the label's contraindications. It does not say whether the jawline indication is limited to a specific age group or patient profile. It also does not say when, or whether, other markets will file for the jawline. Galderma has not said what the product will cost in Mexico or whether it is already on shelves there.

Business information, not medical or legal advice. Verify regulatory status at FDA.gov.

Source: original report ↗

Business information, not medical or legal advice. Verify product status at FDA.gov.

Free alerts

Free: recall & rule-change alerts for your practice.

Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.

The free Inside MedSpa brief · no card · unsubscribe anytime. Privacy.

Share

https://insidemedspa.com/article/mexico-approves-restylane-shaype-jawline-first/

Discussion

    Leave a comment

    Comments are reviewed before they appear.
    Inside MedSpa · Free brief

    By the time it's news, it's too late.

    FDA decisions, recalls and the rules you operate under, drafted from the source documents and sent free by email.

    Get the free brief The free Inside MedSpa brief · no card · unsubscribe anytime.
    FDA, recalls and rule changes for practice owners Get the free brief →